Sionex announces that the US Patent Office has issued a further seven patents to add to its existing portfolio
The newly issued US patents;.
7,119,328 B2 System for DMS peak resolution.
7,098,449 Spectrometer chip assembly.
7,091,481 B2 Method and apparatus for plasma generation.
7,075,068 B2 Method and apparatus for electrospray augmented high field asymmetric ion mobility spectrometer.
7,045,776 B2 System for collection of data and identification of unknown ion species.
7,030,372 Micromachined field asymmetric ion mobility filter and detection.
7,057,168 Systems for differential mobility analysis.
These newly issued patents add to Sionex's core IP for the microDMx technology and further extend its applicability for a wide range of analysis, monitoring and detection scenarios.
The microDMx technology allows the detection of chemical compounds down to parts per trillion (ppt) levels with a degree of specificity unmatched by any other current technology.
"Sionex is continually strengthening our patent portfolio as a key strategy," said Raanan Miller, Sionex's founder and chief technology officer.
"Part of that strategy is to foster and develop key relationships and collaborations with world-class research institutes and academia.
"We still have an extremely close relationship with the Charles Stark Draper Laboratory in Cambridge, MA, for developments and improvements to our technology".
Sionex was founded in 2001 with technology exclusively licensed from the Charles Stark Draper Laboratory where Sionex has exclusive commercialisation rights to this core IP.
Sionex has existing commercial agreements with Varian, Thermo Electron, and General Dynamics for the detection of industrial chemicals, explosives and chemical warfare agents.
